Boehringer Ingelheim has announced positive Phase II results for its TRPC6 inhibitor in patients with focal segmental glomerulosclerosis (FSGS), showing both efficacy and good tolerability.
This marks the first known clinical demonstration of the therapeutic potential of TRPC inhibition in humans — an exciting milestone for the field.
More on Boehringer’s results here: http://bit.ly/4hlG46V
At Nyrada, we’re also advancing the TRPC story. Our TRPC3/6/7 inhibitor, Xolatryp, recently completed a successful Phase I study demonstrating safety, tolerability, and linear pharmacokinetics.
Xolatryp is now preparing to enter a Phase IIa clinical trial targeting myocardial ischemia–reperfusion injury, an area of significant unmet need.
